We recently interviewed Siegfried Kreuzer ,the CEO of KP2. The interview focused on current trends within the European Medtech space as well as the many sales and training services KP2 provides to their clients. Having several years of experience, Mr. Kreuzer provided his unique insight within the industry. KP2 is the lead sponsor for the European Device & Diagnostic Sales Training & Development Conference in Munich.
After his Electronic Engineering Study from 1980 to 1984 he worked as Sales and Key Account Manager with various international organizations of the high-tech market. His business career at Artesyn Technologies led him from Key Account Manager, Global Account Manager and Managing Director Germany to VP Sales, General Manager Europe as well as Member of the Board of GM and Member of the Supervisory Board of Artesyn Austria AG in 2001.
During this period and as General Manager Europe with Synqor he introduced and established successfully sales processes and focused already on process optimization in complex sales environments. In addition he became Miller Heiman Certified Consultant and implemented these processes with great success in his sales environments.
In 2003, Siegfried Kreuzer started his own business and founded KP² Kreuzer & Partners. In 2007, the legal form has been changed to KP2 GmbH, Kreuzer & Partners. As Alliance Partner KP2 GmbH represents Miller Heiman in Central and Eastern Europe. In addition to the Miller Heiman Sales System, Siegfried Kreuzer and his partners have developed several linking tools for sales organizations to offer a full service system for complex B2B organizations.
We are very excited to announce the addition of Shahid N. Shah the CEO of HITSphere.com & Joel Selzer, Co-Founder & CEO Ozmosis, Inc. to this year’s agenda. It is interesting to see how much the healthcare social media landscape has changed in just one year. Check out the session abstract below:
Where Have We Come in a Year? Social Media and Its Impact on the Healthcare Industry
Today, 650 hospitals now have an active presence on Facebook, YouTube and Twitter and numerous healthcare organizations have turned the corner to engage in conversations online. For example, health systems such as Henry Ford have begun to broadcast surgeries and answer clinical questions live via Twitter, new communities like WiserTogether have made it easier for patients to share novel practices around specific conditions such as pregnancy, and services such as iGuard have changed the way we think about drug safety. The FDA’s public hearings in November also gave hope that the cloud of regulatory uncertainty would soon be lifted and the Dose of Digital Wiki now lists hundreds of active pharmaceutical social media programs. This session will look back on the impact social media has made across the patient and provider landscape, examining specific examples over the past year, and offer a compelling vision of what the future may hold.
For the full conference agenda visit: http://bit.ly/HCNM10
Mention Promo Code #HCNM when you sign up and receive a discount on registration.
Hope to see you there!
Paul Hernandez
Group Marketing Manager
Q1 Productions
500 N. Dearborn Suite 500
Chicago, IL 60654
312.602.9684 Direct
312.602.3834 Fax phernandez@q1productions.com
Q1 Productions recently interviewed William Green, President of CDC Software Enterprise Sales. The interview touched on a number of topics including: the various services CDC Software offers to the life science industry as well as Bill’s opinions regarding the significance of new healthcare legislation and the current economic climate.
CDC Software will be one of the supplier partners of the upcoming Life Science Financial Forum. The event will be held May 9-11th in Phoenix, AZ at the Wigwam Resort and Spa.
William Green is President of CDC Software Enterprise, which provides world class capabilities in Enterprise Resource Planning, Customer Relationship Management and Supply Chain Management. In this role William is responsible for managing business relationships, operations, and customer satisfaction activities. Previously, Mr. Green was Vice President of Enterprise Sales, where he was responsible for the sales and operations of Enterprise capabilities for Life Sciences, Food & Beverage, Chemicals and other key process manufacturing verticals
Mr. Green has more than 15 years of progressive experience in technology solution selling, sales management, regional general management, and global management. Since joining the company in 2001, Mr. Green has held several other senior leadership positions throughout the organization. He also worked with the Front Office sales team building and maintaining relationships with large enterprise organizations that use Pivotal CRM and Saratoga CRM.
Prior to CDC Software, he served as the vice President of Sales for Cube Route, provider of on demand Logistics Services. He also worked for Delano Technologies which offers supply chain and customer relationship management (CRM) capabilities as well as i2 Technologies, a supply chain software solutions provider; and, Xerox Corporation.
Q1 Productions recently interviewed Nick Panko, Vice President at CFO Services. Topics covered included:R&D tax credits for life science companies, uncovering opportunities in the recent health care legislation, and the market potential within the baby boomer demographic.
CFO Services will be one of the supplier partners of the upcoming Life Science Financial Forum. The event will be held May 9-11th in Phoenix, AZ at the Wigwam Resort and Spa.
The Research Credit professionals at CFO Services have the practical experience (audit, documentation, industry) and background (accountants, engineers and attorneys) to provide a ‘heightened’ level of service necessary to successfully file for the R&D credit. CFO Services provides a multiple ‘phase’ strategy in all client engagements and during each engagement, utilizes software tools that can be easily modified to each client company. Client engagements can be all-inclusive or project focused. CFO Services looks to be the best in quality, fees, and service.
Q1 Productions recently interviewed Bob Moore, The North American Service Sales Director for GE Healthcare’s Life Sciences business. The interview focused on implications of the recent economic downturn and changes in health policy for finance executives in the life science industry.
GE Healthcare will be one of the supplier partners of the upcoming The 2010 Life Science Financial Forum. The event will be held May 9-11th in Phoenix, AZ at the Wigwam Resort and Spa.
GE Healthcare Scientific Asset Services offers a comprehensive life-cycle asset management solution, beyond equipment maintenance, designed to help companies improve productivity while reducing costs. Their customized programs can offer solutions for pre-purchase planning, predictive maintenance as well as managing moves, redeployment and disposal of equipment. Only GE has developed state-of-the-art technology to provide business intelligence to help drive informed decision making. All of this delivered by technically competent professionals supported by world class infrastructure.
The recent Pharmaceutical Pricing and Reimbursement Conference was held November 16-17th, in Washington D.C. was Q1 Productions’ first program to concentrate on the challenges the pharmaceutical industry is facing in relation to payment structures and reimbursement of new and existing therapies. This conference brought together several different perspectives and topics from leaders in regulatory, public policy, business development, health outcomes and commercial development. Through out the conference discussions focused on what tools pharmaceutical companies will need as the promise of new policies will change the way companies will define success in the pricing and reimbursement of new and existing products. The role comparative effectiveness will play in the development of new products, how the healthcare reform could bring more government involvement into pricing, as well as understanding how pharmcoeconomics will change entire business models, were a few of the main themes that were discussed over the two day meeting.
Dr. Larry Atkins, Schering Plough (now Merck) started the conference off by taking an in depth look at some of the issues pharmaceutical companies will face surrounding the new reform such as, comparative effectiveness research, 340B, follow-on biologics as well as the notion of a public insurance plan. Michael Ruggiero, Astellas concentrated on another hot topic; Medicare and Medicaid. He focused on how legislation will accelerate changes in the market landscape for new products, how manufactures will have a less prominent role as source of product information as well as policy initiatives that will further empower payers, especially government agencies. Other interesting topics of the day came from Barbara Edelman Lewis, Eisai Pharmaceuticals and her views on global trends in pricing & reimbursement, Tom Mullin and Dr. Gene Reeder, Xcenda discussing how to increase coverage by understanding how to communicate better with payers, and Josephine Sollano, Pfizer using real life experiences to demonstrate how working with R&D earlier in product development can enhance reimbursement outcomes. A dynamic panel discussion on the effect of the aging population on new therapies concluded the first day of the meeting.
Day two began with a very engaging presentation from David Parker,Boston Healthcare, He used several positive case studies that showed; by establishing value for your product you can drive market access. Margaret Pasquale, Warner Chilcott spoke on in house case studies involving using pharmacoeconomics and outcomes research can bring value based agreements a competitive edge for pharmaceutical companies. Other highlights of the day were Mick Kolassa, Medical Marketing Economics; he demonstrated how by using market research and understanding customers, pharmaceutical companies can begin to improve their pricing methods. Nancy Davidson, The Aequitas Group drew from her past experience working for CMS to show how implementing reform initiatives such as, pricing, contracting and utilization will have a profound effect on pharmaceutical and biotech products. Other unique perspectives came from Brian Seiz, Express Scripts describing the role of pharmacy benefit managers, and Nikhil Gadre, Spectrum Pharmaceuticals focused on how understanding and utilizing forecasting can add value to your products. The day ended with a successful presentation from Elise Berliner, AHRQ describing how use of clinical data can improve success in gaining reimbursement.
Overall the conference provided attendees with a chance to engage in thought-provoking conversations and networking amongst peers in the industry. We very much look forward to hosting this event again in 2010! I would like to thank all of our wonderful speakers and sponsors in making our 1st Pharmaceutical Pricing and Reimbursement conference a great success.
Comments on our presenters
Great use of real life experiences!
Spot on performance, wonderful presentation on pricing methods!
Nice explanation of trends in pricing for other countries
Q1 Productions recently interviewed Roshawn Blunt, the Managing Director at The Aequitas Group, on the many challenges US pharmaceutical companies are facing in obtaining pricing & reimbursement for their therapies. The interview focused on the impact of new health policies on the pharmaceutical industry as well as the impact of the continued growth in the generics market.
About the Aequitas Group
The Aequitas Group brands themselves as a boutique healthcare advisory firm that specializes in developing clinical and economic solutions that define product value to third-party payors, hospital administrators, investors, providers, and patients. Using their extensive technical expertise across the payor and purchaser landscape, their consultants identify market trends to position products for maximum patient access.
Q1 Productions recently interviewed Efraim Roe, The Executive Director of Medical Devices at Premier Research, on current challenges for device companies conducting clinical trials in Europe. The interview focused on the impact of new medical device directives as well as developments in the Eastern European Market.
Premier Research is a leading global solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies.
The recent Immunogenicity Testing: Clinical and Regulatory Strategy Conference that took place on October 12-13th at the Intercontinental Baltimore was Q1’s first conference focusing on the biopharmaceutical industry and relevant immunogenicity topics. This meeting brought together thought leaders in regulatory affairs, clinical and pre-clinical development, assay development and other scientists.
The biotech industry has seen significant growth in large molecule discovery, especially in the past decade with nearly 3,00 compounds currently in development.
These products are highly complex derivatives that present extraordinary challenges in their discovery, testing and ultimately their clinical applications. At the same time, these products also present outstanding opportunities and improvements in patient care and disease states; making the discovery and utilization of these products indispensable.
The goal of this conference program was to address the challenges companies face when integrating immunogenicity testing into their preclinical and clinical research. Our audience represented members with little experience in immunogenicity testing while others had years of testing behind them and serious concerns and interest in new methods. With continuing oversight on immunoresponse in patients over varying amounts of time, companies must plan their strategy for meeting their endpoints and standards from regulatory bodies. One speaker’s presentation which drew much attention was Dr. Daniela Verthelyi from Center for Drug Evaluation and Research (CDER). In addition to addressing the possibility of future guidance from the agency; she focused mostly on risk assessment.
The two-day forum included eleven case study presentations and a robust panel discussion including Dr. Geoff Hale from BioAnaLabs, Dr. Lodge from Astarte Biologics and Dr. Afshin Safavi from BioAgilytix. Dr. Zhiyan Liang’s presentation made the case for preclinical testing and touched on study design and interpreting data. Dr. Heather Myler’s Immunogenicity Risk Assessment presentation was extremely well-received and especially relevant to the conference audience.
A key area of discussion for the group in attendance was the use of statistics in data interpretation and cut points. Robin Marsden from Ambrx demonstrated cut point estimation and assay design. Preceding this discussion, Dr. Marsh from Adnexus detailed the opportunities of low immunogenic risk in Adnectin and PROfusion development.
Each presentation brought unique insight and attendees noted the quality of the speakers and audience members, the lively discussion and case study information as most valuable takeaways from the meeting. At Q1 we are excited to expand our conference offering in the Biopharmaceutical area and will continue to develop meetings based on each industry’s largest challenges.
Comments on Participating Speakers:
“Great insight into FDA’s perspective.”
“Great questions and interaction during panel discussion”
“Very clear, well-organized presentations”
“Need more of this kind of subject matter”
Feedback from Market Research Questionnaires:
Of the following concerns, which is the greatest challenge that you feel your company currently faces?
The first Health Care New Media Marketing Conference featured case study presentations from leading minds in the health care industry including: The Mayo Clinic, Duke University Health System, and the Cleveland Clinic.
The conference, which focused on the successful implementation of social media for health care professionals, also explored issues such as the future implications of electronic health records, as well as the value of content management systems.
Building upon the success of the last year’s conference, the 2010 event will address how new communication innovations and the recent social media boom have affected marketing strategies for health care professionals.
We are currently looking for health care executives who have successfully executed new media campaigns for their organization.
If you are interested in presenting a case study please submit your abstract to Emily Friedman at efriedman@q1productions.com
To see feedback from the 2009 conference Click Here
We recently interviewed Siegfried Kreuzer ,the CEO of KP2. The interview focused on current trends within the European Medtech space as well as the many sales and training services KP2 provides to their clients. Having several years of experience, Mr. Kreuzer provided his unique insight within the industry. KP2 is the lead sponsor for the European Device & Diagnostic Sales Training & Development Conference in Munich.
Q1 Productions recently interviewed William Green, President of CDC Software Enterprise Sales. The interview touched on a number of topics including: the various services CDC Software offers to the life science industry as well as Bill’s opinions regarding the significance of new healthcare legislation and the current economic climate.
Q1 Productions recently interviewed Nick Panko, Vice President at CFO Services. Topics covered included:R&D tax credits for life science companies, uncovering opportunities in the recent health care legislation, and the market potential within the baby boomer demographic.
Q1 Productions recently interviewed Bob Moore, The North American Service Sales Director for GE Healthcare’s Life Sciences business. The interview focused on implications of the recent economic downturn and changes in health policy for finance executives in the life science industry.
Q1 Productions recently interviewed Roshawn Blunt, the Managing Director at 
